AstraZeneca in 2023 exceeded its long-term revenue goals, by seeing sales worth approximately $45.8bn (€41.55bn). It also revealed that it was planning to launch 20 new medications by 2030.

AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M October 04, 2023 — 08:17 am EDT Written by Zacks Equity Research for Zacks -> ...

Britain's AstraZeneca has agreed to pay $425 million to settle about 11,000 lawsuits in the United States that claimed its heartburn drugs Nexium and Prilosec caused chronic kidney disease.

AstraZeneca (AZN) Key Drugs to Aid Growth, Pipeline Strong October 02, 2023 — 10:00 am EDT Written by Zacks Equity Research for Zacks -> ...

AstraZeneca's sales of cancer drugs helped the pharmaceutical firm beat first-quarter estimates for earnings and revenue. Sales of oncology treatments rose 23%, and those for medicines made with ...

AstraZeneca on Thursday said it was poised to grow in 2023 and beyond, banking on its burgeoning line-up of cancer, metabolic and rare disease drugs to pick up the pace from dwindling COVID ...

AstraZeneca Plc’s lung and breast cancer drugs significantly slowed the spread of disease in two trials, potentially establishing the medicines as the new standard of care for some patients.

AstraZeneca will pay $425 million to settle lawsuits on behalf of consumers who suffered kidney injuries while using its heartburn medications Nexium and Prilosec. AstraZeneca in a statement said ...